APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and
duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or
azacitidine alone.